Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 8/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 0.77 |
| ▸ | MAOB | P27338 | 1/20 | 0.77 |
| ▸ | RXRA | P19793 | 2/20 | 0.76 |
| ▸ | RXRB | P28702 | 2/20 | 0.76 |
| ▸ | RXRG | P48443 | 2/20 | 0.76 |
| ▸ | MRGPRX4 | Q96LA9 | 9/20 | 0.72 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.67 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29784229 | 1.00 | NR4A2 (1.00) | NR4A2MAOAMAOBRXRARXRB | |
| SCHEMBL4406160 | 0.89 | NR4A2 (0.87) | NR4A2MRGPRX4 | |
| SCHEMBL8694329 | 0.87 | MAOB (1.00) | NR4A2MAOAMAOBRXRARXRB | |
| SCHEMBL15452539 | 0.87 | NR4A2 (0.77) | NR4A2MAOAMAOBRXRARXRB | |
| SCHEMBL9586293 | 0.87 | NR4A2 (0.77) | NR4A2MAOAMAOBRXRARXRB | |
| SCHEMBL29784197 | 0.87 | RXRA (1.00) | NR4A2MAOAMAOBRXRARXRB | |
| SCHEMBL7052037 | 0.87 | NR4A2 (1.00) | NR4A2MAOAMAOBRXRARXRB | |
| SCHEMBL6522344 | 0.87 | RXRA (1.00) | NR4A2MAOAMAOBRXRARXRB | |
| SCHEMBL1122713 | 0.86 | NR4A2 (0.94) | NR4A2MAOBMRGPRX4NR4A1NR4A3 | |
| SCHEMBL339009 | 0.86 | NR4A2 (1.00) | NR4A2MAOBMRGPRX4NR4A1NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3694840-B1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | NR4A2 4745/4885MAOA 583/4885MAOB 237/4885 |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | MAGI3, PYM1, MAG | NR4A2 4745/4885MAOA 583/4885MAOB 237/4885 |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | NR4A2 2634/4885MAOA 97/4885MAOB 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.